Local treatment of HVJ-E with T cell costimulatory molecule stimulation elicits systemic anti-tumor effects

Mol Ther Oncol. 2024 Oct 10;32(4):200893. doi: 10.1016/j.omton.2024.200893. eCollection 2024 Dec 19.

Abstract

The tumor-infiltrating lymphocyte (TIL) is a crucial factor in controlling tumor growth. A therapeutic method activating TIL is desired for treating patients with metastatic tumors. Here, we show that treating a local tumor with a combination therapy of UV-irradiated hemagglutinating virus of Japan envelope (HVJ-E) plus agonist antibodies, including OX40, against T cell costimulatory molecules induces systemic anti-tumor effects in a T cell-dependent manner in multiple cancer cell lines. Transcriptome and T cell receptor repertoire analyses revealed that HVJ-E + anti-OX40 antibody treatment activates CD4 and CD8 T cells and promotes T cell trafficking between tumors. These systemic anti-tumor effects required an association between Nkg2d and Nkg2d ligands. Our findings provide insights into how systemic anti-tumor effects are induced and may help the development of therapeutic strategies for eliciting such effects.

Keywords: 4-1BB; HVJ; HVJ-E; Nkg2d; Nkg2d ligand; OX40; Sendai virus; abscopal effects; local treatment; tumor immunity.